JP2025508337A5 - - Google Patents
Info
- Publication number
- JP2025508337A5 JP2025508337A5 JP2024544912A JP2024544912A JP2025508337A5 JP 2025508337 A5 JP2025508337 A5 JP 2025508337A5 JP 2024544912 A JP2024544912 A JP 2024544912A JP 2024544912 A JP2024544912 A JP 2024544912A JP 2025508337 A5 JP2025508337 A5 JP 2025508337A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- antisense oligonucleotide
- conjugated antisense
- exon
- following sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263303577P | 2022-01-27 | 2022-01-27 | |
| US63/303,577 | 2022-01-27 | ||
| PCT/CA2023/050096 WO2023141710A1 (en) | 2022-01-27 | 2023-01-26 | Pre-mrna slice modulating peptide-conjugated antisense therapeutics for the treatment of diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508337A JP2025508337A (ja) | 2025-03-26 |
| JP2025508337A5 true JP2025508337A5 (OSRAM) | 2026-02-03 |
Family
ID=87469898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544912A Pending JP2025508337A (ja) | 2022-01-27 | 2023-01-26 | 疾患治療用のプレｍＲＮＡスライス調節ペプチド共役アンチセンス治療剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250114464A1 (OSRAM) |
| EP (1) | EP4469576A4 (OSRAM) |
| JP (1) | JP2025508337A (OSRAM) |
| CN (1) | CN119137274A (OSRAM) |
| CA (1) | CA3243078A1 (OSRAM) |
| WO (1) | WO2023141710A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| JP7611825B2 (ja) | 2018-08-02 | 2025-01-10 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CA3137715A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9161948B2 (en) * | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| US9801948B2 (en) * | 2011-09-21 | 2017-10-31 | Yale University | Antimicrobial compositions and methods of use thereof |
| WO2021003573A1 (en) * | 2019-07-09 | 2021-01-14 | The Governors Of The University Of Alberta | Exons 45-55 skipping using mutation-tailored cocktails of antisense morpholinos in the dmd gene |
| JP7684971B2 (ja) * | 2019-12-20 | 2025-05-28 | ピーワイシー セラピューティクス リミテッド | 新規の細胞内送達方法 |
-
2023
- 2023-01-26 US US18/730,955 patent/US20250114464A1/en active Pending
- 2023-01-26 JP JP2024544912A patent/JP2025508337A/ja active Pending
- 2023-01-26 WO PCT/CA2023/050096 patent/WO2023141710A1/en not_active Ceased
- 2023-01-26 EP EP23745765.0A patent/EP4469576A4/en active Pending
- 2023-01-26 CA CA3243078A patent/CA3243078A1/en active Pending
- 2023-01-26 CN CN202380028701.3A patent/CN119137274A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023123491A5 (OSRAM) | ||
| JP6954843B2 (ja) | ペプチドオリゴヌクレオチドコンジュゲート | |
| JP7269968B2 (ja) | ペプチド担体上の多重オリゴヌクレオチド部分 | |
| JP6077543B2 (ja) | ペプチド | |
| JP2023544683A5 (OSRAM) | ||
| FI4211231T3 (fi) | Peptidimodifioitu aav-kapsidi | |
| JPWO2023026994A5 (OSRAM) | ||
| JP2018530560A5 (OSRAM) | ||
| JP2010533171A5 (OSRAM) | ||
| US20240254464A1 (en) | Cleavage-inactive cas12f1, cleavage-inactive cas12f1-based fusion protein, crispr gene-editing system comprising same, and preparation method and use thereof | |
| TW201828996A (zh) | 用於肌肉萎縮症之外顯子跳躍寡聚物結合物 | |
| JP2004528266A (ja) | 薬物送達用組成物 | |
| CN114901823A (zh) | 诱导外显子50的跳读的反义核酸 | |
| FI4536686T3 (fi) | Lihaksen parannetun transduktiotehokkuuden omaava peptidimodifioitu aav-kapsidi | |
| Altrichter et al. | Simultaneous targeting of two master regulators of apoptosis with dual-action PNA–and DNA–peptide conjugates | |
| US20040072743A1 (en) | Pharmaceutical composition of modified pna molecules | |
| JP2019523302A5 (OSRAM) | ||
| CN118043461A (zh) | 方法 | |
| JP2022511055A5 (OSRAM) | ||
| US11898145B2 (en) | Enhanced oligonucleotides for inhibiting RTEL1 expression | |
| WO1996035705A1 (en) | Inhibition of transcription factor-mediated transcriptional activation by oligomer strand invasion | |
| US20080038349A1 (en) | Peptide-Pna Chimera Targeting Inducible Nitric Oxide Synthetase | |
| WO2025090254A1 (en) | Adnp syndrome antisense treatment | |
| HK40078573A (en) | Antisense nucleic acid that induces skipping of exon 50 | |
| JP2023540052A5 (OSRAM) |